Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab + Azacitidine in MDS
NCT00997243Phase 2Terminated
- Start
- Nov 2009
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of lintuzumab in myelodysplastic syndrome (MDS). Started Nov 2009; status: terminated.
02
Drugs
lintuzumab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00997243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00997243.